New Zealand’s most experienced COVID-19 vaccine researcher Vaccine Corporation (CVC) has signed a collaboration agreement with the nonprofit Vaccine Formulation Institute (VFI) in Switzerland.
CVC began its vaccine production efforts in 2020 and continues to make progress with its COVID-19 T cell vaccine. The CVC vaccine is designed to induce immunity against current and as yet unknown variants of the SARS-CoV-2 virus, and will act as an activator of existing vaccines currently available on the market.
âIt’s especially exciting to work with VFI. We are now working with people who are global experts in the use, application and formulation of vaccine adjuvants. We’ve been talking to them for some time now, and with the good progress we’re making in the lab, we’re optimistic for the future, âsaid CVC CEO Dr. Robert Feldman.
The multinational collaboration will see the two organizations combine their efforts to formulate the candidate CVC vaccine with adjuvants. Adjuvants are substances commonly used in vaccines that enhance the immune response of the human body.
âWe are delighted to initiate a collaboration with CVC. This is to advance the development of CVC SARS-CoV-2 T cell polypeptide antigen by providing VFI adjuvants and formulation expertise. VFI adjuvants have been shown to improve the immunogenicity of other COVID-19 vaccine candidates in preclinical and clinical studies, and will now be studied in combination with CVC T cell antigen, âsaid Dr. Patrice Dubois, co-founder and scientific director of VFI. .
CVC is developing a unique and proprietary COVID-19 cytotoxic T cell vaccine and has benefited from its collaboration with local and international partners including the University of Auckland, Callaghan Innovation, Scion, Ardigen, Fonterra and the University of Queensland .
Â© Scoop Media